Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors
/in Dendritic Cells, Hypernephroma, International PublicationsA review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International PublicationsAutologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond
/in Dendritic Cells, Hypernephroma, International PublicationsNovel immunotherapy combinations for genitourinary cancers
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial CarcinomaNew treatment modalities with vaccine therapy in renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International PublicationsVaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial CarcinomaCurrent status of clinical trials assessing oncolytic virus therapy for urological cancers
/in Hypernephroma, International Publications, Newcastle Disease Virus, Prostate Cancer, Urothelial CarcinomaImmunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International PublicationsRecent advances in immuno-oncology and its application to urological cancers
/in Dendritic Cells, Hypernephroma, International Publications, Newcastle Disease Virus, Prostate Cancer, Urothelial Carcinoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- The Complexity of Malignant Glioma Treatment
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature